RxDoctor Payments Data

Gregory Pinto, MD

Ophthalmology · Saratoga Spirngs, NYNPI 1316082068

Payments from drug & device makers

$3,717in general payments, 2019–2025

Across 126 payments — averaging $29.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$643
  • Alcon$507
  • Aerie Pharmaceuticals, Inc.$318
  • Tarsus Pharmaceuticals, Inc.$280
  • Amgen$250
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$230
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,702100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,717 in reported general payments places this provider in the 70th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$165,047
Medicare patients
644
Services billed
1,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine36$36,531
Lotemax SmLoteprednol Etabonate143$35,240
LumiganBimatoprost38$23,029
ProlensaBromfenac Sodium49$17,028
XiidraLifitegrast12$13,114
Cyclosporine27$11,525
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol38$9,905
Travoprost20$8,085
MoxifloxacinMoxifloxacin Hcl214$4,919
Latanoprost280$4,646
Timolol Maleate40$3,638
Bromfenac Sodium17$2,480
Tobramycin-DexamethasoneTobramycin/Dexamethasone44$1,770
Brimonidine Tartrate17$1,249
Prednisolone Acetate29$917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$155$59,56074 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa$230$52,268192 claims
Bausch & Lomb Americas Inc.Xiidra$643$13,11412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Saratoga Spirngs

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →